



Four novel gelsedine-type oxindole alkaloids from *Gelsemium elegans*

Yousuke Yamada, Mariko Kitajima, Noriyuki Kogure, Hiromitsu Takayama*

Graduate School of Pharmaceutical Sciences, Chiba University, 1-33 Yayoi-cho, Inage-ku, Chiba 263-8522, Japan

ARTICLE INFO

Article history:

Received 20 May 2008

Received in revised form 7 June 2008

Accepted 9 June 2008

Available online 11 June 2008

Keywords:

Gelsemium

Alkaloid

Gelsedine

Gelsenicine

Gelsecrotonidine

Gelsedilam

ABSTRACT

Four new gelsedine-type oxindole alkaloids (**1–4**) were isolated from the leaves and branches of *Gelsemium elegans*, together with 10 known alkaloids. The structures of the new alkaloids were determined by spectroscopic analyses and partial synthesis from known compounds. Gelsecrotonidine (**1**), 14-hydroxygelsecrotonidine (**2**), and 11-methoxygelsecrotonidine (**3**) possess an additional C₂ unit with an acetic acid residue compared to gelsenicine-related monoterpenoid indole alkaloids. 14-Hydroxygelsedilam (**4**) is an 18,19-nor-type monoterpenoid indole alkaloid.

© 2008 Elsevier Ltd. All rights reserved.

1. Introduction

Gelsemium elegans Benth. (Loganiaceae), a toxic plant widely distributed in Southeast Asia, was used in traditional Chinese medicine. Our previous study has proved that the origin of ‘Yakatsu,’ one of the ancient medicines stored in the Shosoin repository in Japan, is *G. elegans*.¹ This plant was used as a remedy for certain kinds of skin ulcers in traditional Chinese medicine and is presumed to have been used as an external medication for dermatitis more than 1250 years ago in Japan. The genus *Gelsemium* comprises three species, all of which are known to be rich sources of alkaloids. To date, more than 70 alkaloids have been isolated and classified into 6 types on the basis of their chemical structures.^{2,3} Recently, we found that among the structurally diverse *Gelsemium* alkaloids, some gelsedine-type compounds showed potent cytotoxic effects on A431 epidermoid carcinoma cells.⁴ In our continuing chemical studies on *Gelsemium* alkaloids,⁵ 4 new gelsedine-type alkaloids, namely, gelsecrotonidine (**1**), 14-hydroxygelsecrotonidine (**2**), 11-methoxygelsecrotonidine (**3**), and 14-hydroxygelsedilam (**4**), were isolated from *G. elegans*, together with 10 known alkaloids (Fig. 1). In this paper, the structural elucidation of these new alkaloids by means of spectroscopic analyses and chemical conversion from known alkaloids is described.




Figure 1. Structures of new alkaloids.

2. Results and discussion


The leaves and branches of *G. elegans* Benth. (711.1 g) were extracted with MeOH to afford the MeOH extract. The MeOH extract was dissolved in H₂O containing a small volume of MeOH and extracted successively with *n*-hexane, AcOEt, 5% MeOH/CHCl₃, and *n*-BuOH to give the *n*-hexane extract, the AcOEt extract, the 5% MeOH/CHCl₃ extract, and the *n*-BuOH extract, respectively. From the 5% MeOH/CHCl₃ extract, 4 new alkaloids, gelsecrotonidine (**1**, 0.6 mg, 0.00008%), 14-hydroxygelsecrotonidine (**2**, 0.8 mg, 0.00011%), 11-methoxygelsecrotonidine (**3**, 0.3 mg, 0.00004%), and 14-hydroxygelsedilam (**4**, 2.2 mg, 0.0003%), were isolated, together with 10 known alkaloids, gelsenicine (**5**),⁶ 14-hydroxygelsenicine (**6**),^{7,8} 14,15-dihydroxygelsenicine,^{5a} 14-acetoxygelsenicine,⁴

* Corresponding author. Tel./fax: +81 43 290 2901.

E-mail address: htakayam@p.chiba-u.ac.jp (H. Takayama).

Table 1¹H (400 MHz) and ¹³C (125 MHz) NMR data for gelsecrotonidine (**1**), 14-hydroxygelsecrotonidine (**2**), and 11-methoxygelsecrotonidine (**3**) in CDCl₃

Position	1		2		3	
	δ_{H}	δ_{C}	δ_{H}	δ_{C}	δ_{H}	δ_{C}
2		171.0		170.6		171.5
3	3.74 (dd, 4.8, 2.1)	74.9	3.68 (br dd, 1.9, 1.9)	79.4	3.71 (dd, 4.3, 1.7)	75.2
5	4.67 (br ddd, 7.7, 5.0, 2.4)	73.7	4.67 (br ddd, 7.6, 5.0, 2.9)	73.1	4.65 (ddd, 7.9, 5.0, 2.4)	73.6
6	2.51 (dd, 15.5, 5.0), 2.35 (dd, 15.5, 2.4)	37.6	2.54 (dd, 15.8, 5.0), 2.38 (dd, 15.8)	37.4	2.47 (dd, 15.4, 5.0), 2.32 (dd, 15.4, 2.4)	37.8
7		55.9		53.8		55.6
8		131.8		131.3		123.7
9	7.54 (d, 7.6)	124.6	7.53 (d, 7.5)	124.6	7.41 (d, 8.3)	125.4
10	7.08 (ddd, 7.6, 7.6, 1.0)	123.4	7.10 (ddd, 7.5, 7.5, 1.1)	123.6	6.57 (dd, 8.3, 2.4)	107.8
11	7.27 (ddd, 7.6, 7.6, 1.0)	128.2	7.29 (ddd, 7.5, 7.5, 1.1)	128.5		160.2
12	6.89 (d, 7.6)	106.6	6.89 (d, 7.5)	106.9	6.47 (d, 2.4)	94.0
13		138.1		138.1		139.2
14	2.41 (dd, 14.9, 2.1), 2.24 (ddd, 14.9, 9.5, 4.8)	27.9	4.49 (d, 1.9)	67.0	2.38 (dd, 15.0, 1.7), 2.23 (ddd, 15.0, 9.5, 4.3)	27.8
15	3.33 (dd, 9.5, 9.5)	39.4	3.33 (br d, 8.5)	49.2	3.32 (dd, 9.5, 9.5)	39.4
16	2.64 (m)	39.8	2.67 (br ddd, 8.5, 8.5, 3.4)	38.3	2.63 (m)	39.8
17	4.34 (dd, 11.3, 2.8), 4.30 (dd, 11.3, 1.8)	61.9	4.50 (dd, 10.9, 3.4), 4.37 (d, 10.9)	61.6	4.33 (dd, 11.2, 3.0), 4.29 (dd, 11.2, 1.5)	61.9
18	2.59 (3H, br d, 1.3)	14.8	2.58 (3H, br d, 1.4)	14.8	2.58 (3H, d, 0.7)	14.8
19		149.0		148.6		149.0
20		179.7		176.5		179.7
21	6.20 (br d, 1.3)	122.7	6.41 (br d, 1.4)	123.2	6.20 (br d, 0.7)	122.6
22		167.0		167.0		167.0
23	3.77 (3H, s)	51.4	3.78 (3H, s)	51.4	3.77 (3H, s)	51.4
N _A -OMe	3.92 (3H, s)	63.3	3.92 (3H, s)	63.4	3.91 (3H, s)	63.4
11-OMe					3.81 (3H, s)	55.6

**Figure 2.** Selected HMBC and NOE correlations of gelsecrotonidine (**1**).


19-oxogelsenicine,⁸ 14-hydroxy-19-oxogelsenicine,⁸ gelsemoxonine,^{5a} 19(Z)-akuammidine,⁸ 11-methoxyhumantenine,⁹ and gelsemine,^{10,11} by a combination of column chromatographies.

New alkaloid **1**, named gelsecrotonidine, was found to have the molecular formula C₂₂H₂₄N₂O₅ from HREIMS [*m/z* 396.1677 (M⁺)]. ¹H and ¹³C NMR spectra (Table 1) revealed some readily assignable signals due to the gelsenicine (**5**) skeleton, including signals assigned to an oxindole system with a nonsubstituted A ring [δ_{H} 7.54 (d, H-9), δ_{H} 7.27 (ddd, H-11), δ_{H} 7.08 (ddd, H-10), δ_{H} 6.89 (d, H-12), δ_{C} 171.0 (C-2)], an N_A-methoxy group [δ_{H} 3.92 (3H, s)], an oxymethylene group [δ_{H} 4.34 (dd), δ_{H} 4.30 (dd), δ_{C} 61.9 (C-17)], and an oxymethine group [δ_{H} 3.74 (dd), δ_{C} 74.9 (C-3)]. Instead of signals due to H-19 methylene protons, signals assignable to a tri-substituted olefin group [δ_{H} 6.20 (br d, H-21), δ_{C} 149.0 (C-19), δ_{C} 122.7 (C-21)] and a methyl carboxylate group [δ_{H} 3.77 (3H, s, H₃-23), δ_{C} 167.0 (C-22), δ_{C} 51.4 (C-23)] were observed. By examining HMBC correlations of the olefinic proton signal at δ 6.20 (H-21) to the methyl carbon signal at δ 14.8 (C-18), the olefinic carbon signal

at δ 149.0 (C-19), and the imine carbon signal at δ 179.7 (C-20) as well as the proton signal at δ 2.59 (H₃-18) to the olefinic carbon signal at δ 122.7 (C-21), a crotonic acid methyl ester residue comprising C-18 and C-19 was confirmed to be connected to the C-20 imine carbon, as shown in Figure 2. The geometry of the double bond between C-19 and C-21 was elucidated to be *E* based on the NOE correlation of H-21 (δ 6.20) to H-15 (δ 3.33). From these data, gelsecrotonidine (**1**) was proposed to be a gelsenicine (**5**) derivative having a methyl acetate residue on C-19 position.

To confirm the structure inferred by spectroscopic analyses above, the chemical transformation of gelsenicine (**5**) into **1** was attempted (Scheme 1). Gelsenicine (**5**) was treated with methyl glyoxylate¹² in the presence of a catalytic amount of TFA in CH₂Cl₂ to give **1** in 86% yield. All of the spectroscopic data including the CD spectrum of semi-synthetic **1** were identical with those of the natural product, thereby establishing the structure including the absolute configuration. To the best of our knowledge, gelsecrotonidine (**1**) is the first example of a monoterpenoid indole alkaloid having a C₂ unit with an acetic acid residue on the side chain.

New alkaloid **2** was shown to have the molecular formula C₂₂H₂₄N₂O₆ from HREIMS [*m/z* 412.1636 (M⁺)], which indicated that **2** had an extra oxygen compared to gelsecrotonidine (**1**). ¹H and ¹³C NMR spectral data revealed the same backbone structure as **1**, namely, four aromatic protons [δ 7.53 (d, H-9), δ 7.29 (ddd, H-11), δ 7.10 (ddd, H-10), δ 6.89 (d, H-12)], an N_A-methoxy group [δ 3.92 (3H, s)], oxymethylene protons [δ 4.50 (dd), δ 4.37 (d) (H₂-17)], an oxymethine proton [δ 3.68 (br-dd, H-3)], and a methyl crotonate residue [δ_{H} 6.41 (br d, H-21), δ_{H} 3.78 (3H, s, H₃-23), δ_{H} 2.58 (3H, br d,

**Scheme 1.**

H₃-18), δ_{C} 167.0 (C-22), δ_{C} 148.6 (C-19), δ_{C} 123.2 (C-21), δ_{C} 51.4 (C-23), δ_{C} 14.8 (C-18)]. In addition, a low-field methine proton signal at δ 4.49 (d, H-14) and an oxygenated methine carbon signal at δ_{C} 67.0 were observed, suggesting the existence of an additional hydroxyl group. HMBC correlations of the proton signal at δ 3.68 due to H-3 and that at δ 3.33 due to H-15 to the carbon signal at δ 67.0 indicated that the hydroxyl group was attached to C-14. The configuration of the hydroxyl group at C-14 was shown to be β on the basis of the coupling constant ($J_{3,14}=1.9$ Hz) of the proton at C-14, as in the case of other compounds having a hydroxyl or acetoxy group at C-14.^{4,5b,d} The *E* configuration of the C-19–C-21 double bond was determined by NOE correlation of H-21 to H-15. From the above data, new alkaloid **2** was deduced to be a 14 β -hydroxy derivative of gelsecrotonidine (**1**). To confirm the structure, 14-hydroxygelsenicine (**6**), a 14 β -hydroxy derivative of gelsenicine (**5**), was treated with methyl glyoxylate according to the method for the partial synthesis of gelsecrotonidine (**1**) to give **2** in 82% yield. All of the spectroscopic data including the CD spectrum of semi-synthetic **2** were identical with those of the natural product, thereby establishing the structure including the absolute configuration.

New alkaloid **3** was found to have the molecular formula C₂₃H₂₆N₂O₆ from HREIMS [m/z 426.1791 (M^+)], which indicated that **3** had an extra CH₂O compared to gelsecrotonidine (**1**). ¹H and ¹³C NMR spectral data revealed the same backbone structure as gelsecrotonidine (**1**), including a methyl crotonate residue [δ_{H} 6.20 (br d, H-21), δ_{H} 3.77 (3H, s, H₃-23), δ_{H} 2.58 (3H, d, H₃-18), δ_{C} 167.0 (C-22), δ_{C} 149.0 (C-19), δ_{C} 122.6 (C-21), δ_{C} 51.4 (C-23), δ_{C} 14.8 (C-18)], except for the signals in the aromatic region. NMR data suggested the presence of an N_a,6-dimethoxyoxindole system [δ_{H} 7.41 (d, H-9), δ_{H} 6.57 (dd, H-10), δ_{H} 6.47 (d, H-12), δ_{H} 3.91 (3H, s, N_a-OMe), δ_{H} 3.81 (3H, s, 11-OMe), δ_{C} 171.5 (C-2), δ_{C} 63.4 (N_a-OMe), δ_{C} 55.6 (11-OMe)]. UV spectra [293.0 (sh), 249.0 (sh), 218.5] also supported the presence of a 6-methoxyoxindole chromophore. HMBC crosspeaks of the methoxy proton signal at δ 3.81 (11-OMe) to the aromatic carbon signal at δ 160.2 (C-11) and of the proton signal at δ 6.57 (dd, H-10) to the quaternary sp² carbon signal at δ 123.7 (C-8) indicated that a methoxy group was attached to C-11 in the A ring of the oxindole. From the above data, new alkaloid **3** was deduced to be an 11-methoxy derivative of gelsecrotonidine (**1**). To reveal the structure of **3**, partial synthesis from 4,20-dehydrogelsemicine (**7**),^{5b,13} an 11-methoxy derivative of gelsenicine (**5**), to afford **3** was accomplished in 42% yield. All of the spectroscopic data including the CD spectrum of semi-synthetic **3** were identical with those of the natural product, thereby establishing the structure including the absolute configuration.


New alkaloid **4** was shown to have the molecular formula C₁₇H₁₈N₂O₅ from HREIMS [m/z 330.1213 (M^+)], which possessed two carbons less than common *Gelsemium* alkaloids. UV and NMR spectra exhibited the characteristic N_a-methoxyoxindole chromophore. ¹H and ¹³C NMR data (Table 2) revealed the presence of a nonsubstituted A ring of the oxindole system, an N_a-methoxy group (δ_{H} 3.87, δ_{C} 64.0), two oxymethine groups (δ_{H} 4.41, δ_{C} 62.1, C-14, and δ_{H} 3.56, δ_{C} 80.5, C-3), a methine group bearing nitrogen (δ_{H} 3.99, δ_{C} 57.8, C-5), and an oxymethylene group (δ_{H} 4.27, 4.20 δ_{C} 67.5, C-17). In addition to the carbonyl carbon signal due to the oxindole nucleus at δ 172.9, a lactam carbonyl carbon signal at δ 179.6 was observed in the ¹³C NMR spectra. These spectral data were very similar to those of gelsedilam,^{5d} which had an 18,19-nor-gelsedine backbone structure, except for the existence of a low-field methine function (δ_{H} 4.41, δ_{C} 62.1), suggesting the addition of a hydroxyl group. ¹H–¹H COSY correlation between the H-3 oxymethine proton signal at δ 3.56 and the low-field methine proton signal at δ 4.41 indicated that a hydroxyl group was attached to C-14. The configuration of the hydroxyl group at C-14 was shown to be β on the basis of the coupling constant ($J_{3,14}=2.2$ Hz) of the proton at C-14.

Table 2¹H (400 MHz) and ¹³C (125 MHz) NMR data for 14-hydroxygelsedilam (**4**) in CD₃OD

Position	4	
	δ_{H}	δ_{C}
2		172.9
3	3.56 (br s)	80.5
5	3.99 (m)	57.8
6	2.39 (dd, 15.7, 3.8), 1.91 (br dd, 15.7, 2.5)	37.4
7		55.1
8		132.8
9	7.47 (d, 7.7)	125.8
10	7.04 (ddd, 7.7, 7.7, 1.1)	124.8
11	7.24 (ddd, 7.7, 7.7, 1.1)	129.6
12	6.90 (d, 7.7)	108.1
13		139.3
14	4.41 (br d, 2.2)	62.1
15	2.44 (d, 8.4)	47.7
16	2.79 (m)	37.0
17	4.27 (dd, 10.9, 3.0), 4.20 (d, 10.9)	67.5
20		179.6
N _a -OMe	3.87 (3H, s)	64.0

Therefore, **4** was deduced to be a 14 β -hydroxy derivative of gelsedilam.

To confirm the structure of **4** proposed by spectroscopic analysis, partial synthesis using 14-hydroxygelsenicine (**6**) as starting material was performed (Scheme 2). 14-Hydroxygelsenicine (**6**) was treated with trichloroethoxycarbonyl (Troc) chloride in the presence of Et₃N in CH₂Cl₂ to give enamine-carbamate **8** in 68% yield. Treatment of **8** with *m*-CPBA afforded lactam **9** in 70% yield. Finally, removal of the N_b-Troc group (Zn, AcOH) gave 14-hydroxygelsedilam (**4**) in 71% yield. All of the spectroscopic data including the CD spectrum of synthetic **4** were identical with those of natural **4** and, therefore, the structure including the absolute configuration was established.



In conclusion, four new gelsedine-type oxindole alkaloids (**1–4**) were isolated from the leaves and branches of *G. elegans*. To the best of our knowledge, gelsecrotonidine (**1**), 14-hydroxygelsedilam (**2**), and 11-methoxygelsedilam (**3**) are the first examples of a monoterpene indole alkaloid possessing a C₂ unit with an acetic acid residue on the side chain.

3. Experimental

3.1. General

¹H and ¹³C NMR spectra: JEOL JNM ECP-400 at 400 MHz (¹H) and JEOL JNM A-500 at 125 MHz (¹³C), respectively. UV: JASCO V-560. EIMS and HREIMS: JEOL GC mate. CD: JASCO J-720WI. TLC:

precoated silica gel 60 F₂₅₄ plates (Merck, 0.25 mm thick). Column chromatography: Silica gel 60 (Merck, 70–230 mesh). Column chromatography: Silica gel 60N [Kanto Chemical, 40–50 mm (for flash chromatography)] and Chromatorex NH [Fuji Silysia Chemical, 100–200 mesh (for amino-silica gel column chromatography)]. Medium pressure liquid chromatography (MPLC): C.I.G. prepacked column CPS-HS-221–05 (Kusano Kagakukikai, SiO₂).

3.2. Plant material

G. elegans Benth. was collected from the Atagawa Tropical and Alligator Garden in Izu, Japan, in April 2002 (branches 529.7 g) and in March 2006 (branches 82.4 g, and leaves 99.0 g), and identified by Dr. F. Ikegami, Chiba University. A voucher specimen was deposited at the Faculty of Pharmaceutical Sciences, Chiba University.

3.3. Extraction and isolation

The leaves and branches of *G. elegans* Benth. (711.1 g, dry weight) were extracted with MeOH (once at room temperature and three times under reflux) to give the MeOH extract (88.36 g). The MeOH extract was dissolved in 8% MeOH/H₂O (1.0 L) and extracted with *n*-hexane (1.0 L, 0.4 L, 0.5 L) to give the *n*-hexane extract (12.30 g). The aqueous layer was successively extracted with AcOEt (1.0 L, 0.8 L, 0.8 L), 5% MeOH/CHCl₃ (1.0 L×3), and *n*-BuOH (0.8 L×3) to give the AcOEt extract (19.22 g), the 5% MeOH/CHCl₃ extract (1.28 g), and the *n*-BuOH extract (20.86 g), respectively. The 5% MeOH/CHCl₃ extract (1.28 g) was separated by SiO₂ flash column chromatography with a CHCl₃/MeOH gradient to afford eight fractions: fr. A 2% MeOH/CHCl₃ (160 mL, 21.9 mg); fr. B 2% MeOH/CHCl₃ (120 mL, 9.2 mg); fr. C 2% MeOH/CHCl₃ (200 mL, 457.0 mg); fr. D 5% MeOH/CHCl₃ (360 mL, 177.3 mg); fr. E 5% MeOH/CHCl₃ (80 mL, 16.0 mg); fr. F 5% MeOH/CHCl₃ (60 mL, 22.9 mg); fr. G MeOH (60 mL, 464.9 mg); and fr. H MeOH (110 mL, 7.0 mg). Fraction C (457.0 mg) was separated by SiO₂ flash column chromatography with MeOH/AcOEt gradient. The fraction eluted with 2% MeOH/AcOEt was purified by MPLC (7% MeOH/AcOEt and 1% MeOH/CHCl₃) to give gelsecrotonidine (**1**, 0.6 mg) and 11-methoxygelsecrotonidine (**3**, 0.3 mg). The fraction eluted with 2% MeOH/AcOEt was further separated by MPLC (7% MeOH/AcOEt and 7% MeOH/CHCl₃) to give 14-hydroxygelsecrotonidine (**2**, 0.8 mg). The AcOEt-soluble part of fraction G (439.0 mg) was separated by SiO₂ flash column chromatography with MeOH/CHCl₃ gradient. The fraction eluted with 10–20% MeOH/CHCl₃ was purified by MPLC (10% MeOH/CHCl₃) to give 14-hydroxygelsedilam (**4**, 2.2 mg). Ten known alkaloids were isolated. Gelsenicine (**5**, 2.7 mg), 14-acetoxygelsenicine (1.8 mg), 19-oxogelsenicine (0.4 mg), 14-hydroxy-19-oxogelsenicine (1.1 mg), gelsemoxonine (9.0 mg), and 11-methoxyhumantenine (20.1 mg) were isolated from fraction C. 11-Methoxyhumantenine (36.2 mg) was also isolated from fraction D and fraction G. 14,15-Dihydroxygelsenicine (15.5 mg) was isolated from fraction D. 14-Hydroxygelsenicine (**6**, 2.7 mg) was isolated from fraction F and fraction G. 19(*Z*)-Akuammidine (4.5 mg) was isolated from fraction G and gelsemine (7.0 mg) was isolated from fraction H (7.0 mg). The structures of the known compounds were identified by comparing their spectroscopic data with the literature values.

3.4. Characteristics of each alkaloid

3.4.1. Gelsecrotonidine (**1**)

¹H and ¹³C NMR data, see Table 1; UV (MeOH) λ_{max} nm (log ε) 248.5 (4.03), 209.5 (4.30); EIMS *m/z* (%) 396 (M⁺, 100), 365 (57); HREIMS 396.1677 (M⁺, calcd for C₂₂H₂₄N₂O₅, 396.1685); CD (c 0.252 mmol/L, MeOH, 24 °C) Δε (λ nm) 0 (286), –3.47 (256), 0 (239), +0.75 (236), 0 (229), –14.12 (210).

3.4.2. 14-Hydroxygelsecrotonidine (**2**)

¹H and ¹³C NMR data, see Table 1; UV (MeOH) λ_{max} nm (log ε) 248.5 (4.10), 210.5 (4.36); EIMS *m/z* (%) 412 (M⁺, 100), 146 (52); HREIMS 412.1636 (M⁺, calcd for C₂₂H₂₄N₂O₆, 412.1634); CD (c 0.291 mmol/L, MeOH, 24 °C) Δε (λ nm) 0 (346), +0.52 (307), 0 (292), –4.01 (251), –1.00 (237), –13.79 (213).

3.4.3. 11-Methoxygelsecrotonidine (**3**)

¹H and ¹³C NMR data, see Table 1; UV (MeOH) λ_{max} nm (log ε) 293.0 (sh, 3.36), 249.0 (sh, 4.01), 218.5 (4.26); EIMS (%) *m/z* 426 (M⁺, 100), 395 (72), 132 (81); HREIMS 426.1791 (M⁺, calcd for C₂₃H₂₆N₂O₆, 426.1790); CD (c 0.244 mmol/L, MeOH, 24 °C) Δε (nm) 0 (298), –2.17 (256), 0 (242), +1.02 (239), 0 (236), –17.27 (219), 0 (205), +4.36 (201).

3.4.4. 14-Hydroxygelsedilam (**4**)

¹H and ¹³C NMR data, see Table 2; UV (MeOH) λ_{max} nm (log ε) 257.5 (3.52), 209.0 (4.19); EIMS *m/z* (%): 330 (M⁺, 87), 144 (100); HREIMS 330.1213 (M⁺, calcd for C₁₇H₁₈N₂O₅, 330.1215); CD (c 0.280 mmol/L, MeOH, 24 °C) Δε (λ nm) 0 (304), –3.11 (260), 0 (248), +4.33 (235), 0 (224), –12.65 (213).

3.5. Partial synthesis of gelsecrotonidine (**1**), 14-hydroxygelsecrotonidine (**2**), and 11-methoxygelsecrotonidine (**3**)

3.5.1. Conversion of gelsenicine (**5**) into gelsecrotonidine (**1**)

To a stirred solution of gelsenicine (**5**, 3.9 mg, 0.012 mmol) and TFA (5 μL) in CH₂Cl₂ (0.8 mL) was added methyl glyoxylate (0.25 mL, excess), and the mixture was stirred for 4.5 h at room temperature under Ar atmosphere. Saturated aqueous Na₂CO₃ was added to the reaction mixture under ice cooling and the entire mixture was extracted with CHCl₃. The organic layer was washed with brine, dried over MgSO₄, and evaporated. The residue was subjected to amino-silica gel open column chromatography (CHCl₃) to remove excess aldehyde. The fraction eluted with CHCl₃ was purified by SiO₂ open column chromatography (CHCl₃) to afford **1** (3.9 mg, 86%). All the spectroscopic data were identical with those of natural **1**.

3.5.2. Conversion of 14-hydroxygelsenicine (**6**) into 14-hydroxygelsecrotonidine (**2**)

To a stirred solution of 14-hydroxygelsenicine (**6**, 3.6 mg, 0.011 mmol) and TFA (5 μL) in CH₂Cl₂ (0.8 mL) was added methyl glyoxylate (0.25 mL, excess), and the mixture was stirred for 4.5 h at room temperature under Ar atmosphere. Saturated aqueous Na₂CO₃ was added under ice cooling and the entire mixture was extracted with CHCl₃. The organic layer was washed with brine, dried over MgSO₄, and evaporated. The residue was subjected to amino-silica gel open column chromatography (CHCl₃) to remove excess aldehyde. The fraction eluted with CHCl₃ was purified by MPLC (2.5% MeOH/CHCl₃) to afford **2** (3.4 mg, 82%). All the spectroscopic data were identical with those of natural **2**.

3.5.3. Conversion of 4,20-dehydrogelsemicine (**7**) into 11-methoxygelsecrotonidine (**3**)

To a stirred solution of 4,20-dehydrogelsemicine (**7**, 2.0 mg, 0.006 mmol) and TFA (0.2 μL) in CH₂Cl₂ (1.1 mL) was added methyl glyoxylate (0.1 mL, excess), and the mixture was stirred for 5 h at room temperature under Ar atmosphere. Saturated aqueous Na₂CO₃ was added under ice cooling and the entire mixture was extracted with CHCl₃. The organic layer was washed with brine, dried over MgSO₄, and evaporated. The residue was subjected to amino-silica open column chromatography (CHCl₃) to remove excess aldehyde. The fraction eluted with CHCl₃ was purified by MPLC

(0.5% MeOH/CHCl₃) to afford **3** (1.0 mg, 42%). All the spectroscopic data were identical with those of natural **3**.

3.6. Partial synthesis of 14-hydroxygelsedilam (**4**)

3.6.1. Preparation of enamine-carbamate **8** from 14-hydroxygelsenicine (**6**)

To a solution of 14-hydroxygelsenicine (**6**, 5.5 mg, 0.017 mmol) in CH₂Cl₂ (0.5 mL) were added Et₃N (4.3 μ L, 0.034 mmol) and 2,2-trichloroethoxycarbonyl (Troc) chloride (2.7 μ L, 0.019 mmol) at 0 °C under Ar atmosphere. After stirring at room temperature for 3 h, additional Troc chloride (1.3 μ L, 0.009 mmol) was added and the mixture was stirred for 1 h. Saturated aqueous NH₄Cl was added to the reaction mixture and the entire mixture was extracted with CHCl₃. The organic layer was washed with brine, dried over MgSO₄, and evaporated. The residue was purified by MPLC (50% AcOEt/*n*-hexane) to give enamine-carbamate **8** (5.6 mg, 68%).

3.6.1.1. Enamine-carbamate 8. ¹H NMR (400 MHz, CDCl₃) δ 7.48 (1H, d, *J*=7.6 Hz), 7.30 (1H, dd, *J*=7.6, 7.6 Hz), 7.10 (1H, dd, *J*=7.6, 7.6 Hz), 6.92 (1H, d, *J*=7.6 Hz), 6.38 (1H, ddd, *J*=7.1, 7.1, 7.1 Hz), 4.86 (1H, d, *J*=12.0 Hz), 4.69 (1H, d, *J*=12.0 Hz), 4.61 (1H, m), 4.40 (2H, overlapped), 4.34 (1H, d, *J*=11.2 Hz), 3.92 (3H, s), 3.68 (1H, br s), 3.24 (1H, br d, *J*=7.9 Hz), 2.63 (1H, br d, *J*=15.9 Hz), 2.57 (1H, m), 2.30 (1H, dd, *J*=15.9, 3.7 Hz), 1.86 (3H, d, *J*=7.1 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 170.7, 150.2, 140.2, 138.3, 131.1, 128.5, 124.4, 123.5, 107.0, 103.8, 95.5, 79.4, 74.4, 70.2, 63.5, 61.7, 61.3, 53.2, 43.7, 34.8, 33.6, 13.9; UV (MeOH) λ_{\max} nm (log ϵ) 253.5 (sh, 3.47), 209.0 (4.01); EIMS *m/z* (%) 516 (M⁺, 100), 518 (M⁺+2, 97), 520 (M⁺+4, 33); HREIMS 516.0604 (M⁺, calcd for C₂₂H₂₃N₂O₆Cl₃, 516.0621); CD (c 0.282 mmol/L, MeOH, 24 °C) $\Delta\epsilon$ (λ nm) 0 (301), −1.18 (269), 0 (260), +4.67 (232), 0 (223), −30.61 (210).

3.6.2. Oxidative cleavage of **8** with *m*-CPBA

To a solution of enamine-carbamate **8** (5.6 mg, 0.011 mmol) in CH₂Cl₂ (0.2 mL) were added NaHCO₃ (1.0 mg, 0.011 mmol) and a solution of *m*-CPBA (2.2 mg, 0.009 mmol) in CH₂Cl₂ (0.22 mL) at −78 °C under Ar atmosphere. After stirring for 3.5 h, a solution of *m*-CPBA (2.2 mg, 0.009 mmol) in CH₂Cl₂ (0.22 mL) was added and the mixture was stirred for 7 h at −60 °C under Ar atmosphere. The reaction mixture was quenched by adding saturated aqueous NaHSO₃ and extracted with CHCl₃. The organic layer was washed with saturated aqueous NaHCO₃, dried over MgSO₄, and evaporated. The residue was purified by SiO₂ open column chromatography (50% AcOEt/*n*-hexane to 5% MeOH/AcOEt) to afford **9** (3.8 mg, 70%).

3.6.2.1. Compound 9. ¹H NMR (400 MHz, CDCl₃) δ : 7.51 (1H, d, *J*=7.6 Hz), 7.31 (1H, ddd, *J*=7.6, 7.6, 1.2 Hz), 7.12 (1H, ddd, *J*=7.6, 7.6, 1.1 Hz), 6.94 (1H, d, *J*=7.6 Hz), 4.98 (1H, d, *J*=12.0 Hz), 4.78 (1H, d, *J*=12.0 Hz), 4.70 (1H, m), 4.68 (1H, d, *J*=2.4 Hz), 4.42 (1H, dd, *J*=11.3, 3.3 Hz), 4.32 (1H, d, *J*=11.3 Hz), 3.94 (3H, s), 3.85 (1H, br s), 2.97 (1H,

d, *J*=9.0 Hz), 2.86 (1H, m), 2.60 (1H, dd, *J*=16.1, 2.3 Hz), 2.45 (1H, dd, *J*=16.1, 3.9 Hz); ¹³C NMR (100 MHz, CDCl₃) δ : 173.0, 170.7, 149.1, 138.2, 130.4, 128.8, 124.2, 123.8, 107.2, 94.5, 78.7, 74.9, 66.4, 63.7, 60.8, 59.8, 53.4, 48.1, 33.4, 32.6; UV (MeOH) λ_{\max} nm (log ϵ) 257.5 (3.36), 209.5 (4.07); EIMS *m/z* 504 (M⁺, 18), 506 (M⁺+2, 16), 270 (83), 176 (100); HREIMS 504.0266 (M⁺, calcd for C₂₀H₁₉N₂O₇Cl₃, 504.0257); CD (c 0.142 mmol/L, MeOH, 24 °C) $\Delta\epsilon$ (λ nm) 0 (307), −7.26 (259), 0 (245), +8.57 (229), 0 (222), −26.21 (213).

3.6.3. Preparation of 14-hydroxygelsedilam (**4**)

To a solution of **9** (10.0 mg, 0.020 mmol) in AcOH (1.5 mL) was added zinc powder (100 mg, 1.529 mmol). The reaction mixture was stirred for 2 h at room temperature and the zinc powder was removed by filtration. The acidic layer was basified with cold aqueous NH₃ at 0 °C and extracted with 20% MeOH/CHCl₃. The organic layer was washed with brine, dried over MgSO₄, and evaporated. The residue was purified by MPLC (10% MeOH/AcOEt) to give 14-hydroxygelsedilam (**4**, 4.8 mg, 71%). All the spectroscopic data were identical with those of natural **4**.

Acknowledgements

This work was supported by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science, the Research Foundation for Pharmaceutical Sciences, and Takeda Science Foundation.

References and notes

- Kitajima, M.; Arai, Y.; Takayama, H.; Aimi, N. *Proc. Jpn. Acad. Ser. B* **1998**, *74*, 159–163.
- Kitajima, M. *J. Nat. Med.* **2007**, *61*, 14–23.
- Takayama, H.; Sakai, S. *The Alkaloids*; Cordell, G. A., Ed.; Academic: San Diego, CA, 1997; Vol. 49, Chapter 1 and references cited therein.
- Kitajima, M.; Nakamura, T.; Kogure, N.; Ogawa, M.; Mitsuno, Y.; Ono, K.; Yano, S.; Aimi, N.; Takayama, H. *J. Nat. Prod.* **2006**, *69*, 715–718; *J. Nat. Prod.* **2007**, *70*, 142.
- (a) Kitajima, M.; Kogure, N.; Yamaguchi, K.; Takayama, H.; Aimi, N. *Org. Lett.* **2003**, *5*, 2075–2078; (b) Kitajima, M.; Urano, A.; Kogure, N.; Takayama, H.; Aimi, N. *Chem. Pharm. Bull.* **2003**, *51*, 1211–1214; (c) Kogure, N.; Nishiya, C.; Kitajima, M.; Takayama, H. *Tetrahedron Lett.* **2005**, *46*, 5857–5861; (d) Kogure, N.; Ishii, N.; Kitajima, M.; Wongseripipatana, S.; Takayama, H. *Org. Lett.* **2006**, *8*, 3085–3088; (e) Kogure, N.; Someya, A.; Urano, A.; Kitajima, M.; Takayama, H. *J. Nat. Med.* **2007**, *61*, 208–212; (f) Kogure, N.; Kobayashi, H.; Ishii, N.; Kitajima, M.; Wongseripipatana, S.; Takayama, H. *Tetrahedron Lett.* **2008**, *49*, 3638–3642; (g) Kogure, N.; Ishii, N.; Kobayashi, H.; Kitajima, M.; Wongseripipatana, S.; Takayama, H. *Chem. Pharm. Bull.* **2008**, *56*, 870–872.
- Du, X.-B.; Dai, Y.-H.; Zhang, C.-L.; Lu, S.-L.; Liu, Z.-G. *Acta Chim. Sinica* **1982**, *40*, 1137–1141.
- Yang, J.-S.; Chen, Y.-W. *Acta Pharm. Sinica* **1982**, *17*, 633–634.
- Ponglux, D.; Wongseripipatana, S.; Subhadhirasakul, S.; Takayama, H.; Yokota, M.; Ogata, K.; Phisalaphong, C.; Aimi, N.; Sakai, S. *Tetrahedron* **1988**, *44*, 5075–5094.
- Lin, L. Z.; Cordell, G. A.; Ni, C. Z.; Clardy, J. *J. Nat. Prod.* **1989**, *52*, 588–594.
- Lovell, F. M.; Pepinsky, R.; Wilson, A. J. *C. Tetrahedron Lett.* **1959**, 1–5.
- Yeh, S.; Cordell, G. A.; Garland, M. *J. Nat. Prod.* **1986**, *49*, 483–487.
- Haug, B. E.; Rich, D. H. *Org. Lett.* **2004**, *6*, 4783–4786.
- Onanga, M.; Khuong-Huu, F. *C.R. Hebd. Seances Acad. Sci., Ser. C* **1980**, *291*, 191–193.